PubMed Journals Articles About "Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation" RSS

01:28 EST 17th November 2018 | BioPortfolio

Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation articles that have been published worldwide.

More Information about "Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation" on BioPortfolio

We have published hundreds of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation news stories on BioPortfolio along with dozens of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Clinical Trials and PubMed Articles about Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Companies in our database. You can also find out about relevant Assessment Of Biomarkers For Recurrent HCV Infection Post-liver Transplantation Drugs and Medications on this site too.

Showing "Assessment Biomarkers Recurrent Infection Post liver Transplantation" PubMed Articles 1–25 of 29,000+

Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.

Successful eradication of recurrent hepatitis C virus (HCV) infection following liver transplantation (HCV) improves graft survival. The current study aimed at evaluation of hepatic fibrosis changes among long term responders to DAAs therapy for recurrent HCV after liver transplantation using noninvasive methods. Patients with significant hepatic fibrosis (≥F2) who achieved SVR12 after treatment with DAAs for recurrent HCV were included (n=52). Hepatic fibrosis status was assessed, non-invasively, by calc...

Primary infection with human herpes virus type 6, post-pediatric liver transplantation - a pathogen to remember.

In recent years, liver transplantation (LT) has become a well-accepted therapeutic modality for children with end stage liver disease, with transplantation surgery being performed at a younger age. Human herpes virus 6 (HHV-6) infection occurs in most children within the first two years of life, therefore, data on primary HHV-6 infection in pediatric liver transplant recipients is scarce.

SVR is Associated with a Decreased Risk of Post-Transplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C Related Liver Disease.

Post-transplant diabetes mellitus (PTDM), an increasingly recognized complication of solid organ transplantation, is associated with increased morbidity and mortality following liver transplantation. Hepatitis C virus (HCV) infection is a consistent and modifiable risk factor for PTDM. Prior studies have demonstrated improvement in glucose metabolism following sustained virologic response (SVR). However, the effect of SVR on the incidence of PTDM has not been previously investigated in a large cohort of liv...

Association of Pre-Transplant Renal Function with Liver Graft and Patient Survival after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis.

Nonalcoholic Steatohepatitis(NASH) is one of the top three indications for liver transplantation in western countries. It is unknown whether renal dysfunction at the time of liver transplantation has any effect on post-liver transplantation outcomes in recipients with NASH.

Evaluation of published assessment tools for comorbidity in liver transplantation: a systematic review protocol.

Liver transplantation is considered the best therapy option for end-stage liver disease. Different factors including recipient comorbidity at time of transplantation are supposed to have substantial impact on outcomes. Although several studies have focused on comorbidity assessment indices for liver transplant recipients, there is no systematic review available on the methodological details and prognostic accuracy of these instruments. The aim of this study is to systematically review recipient comorbidity ...

Hepatitis E virus genotype 3 is a common finding in liver transplanted patients undergoing liver biopsy for elevated liver enzymes with a low de Ritis ratio and suspected acute rejection: a real world cohort.

Hepatitis E virus (HEV) infection is a potential reason for elevated liver enzymes after liver transplantation (LT). Our aim was to analyze a real world cohort of LT patients, who underwent liver biopsy for elevated transaminases and suspected acute rejection, to evaluate frequency of post-transplant HEV infection.

Reducing posttransplant readmissions: tangible solutions may be within reach.

Liver transplantation (LT) is the most effective, albeit resource-intensive, treatment for end-stage liver disease (ESLD). As LT recipients consume considerable health care resources, hospital readmissions present an opportunity for quality improvement (QI) strategies. Recent national and single-center studies have shown considerable variability in post-LT healthcare utilization and that much of the cost in the first post-LT year, apart from the transplant hospitalization, is driven by readmissions.(1, 2). ...

The road map towards an HCV-free transplant population.

Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the post-transplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pre-transplant patients with advanced liv...

Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury following Orthotopic Liver Transplantation: a systematic review.

Acute kidney injury (AKI) is common after orthotopic liver transplantation (OLT) usually occurring early post-transplant. Multiple causes include graft preservation injury, blood loss, hypotension but also severity of recipient liver disease. Early intervention in AKI has both short and long term patient benefits. Unfortunately there are no current clinical biomarkers of early AKI.

Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.

Live attenuated vaccines are currently contraindicated in solid-organ transplant recipients. However, the risk of vaccine-preventable infections is lifelong, and can be particularly severe after transplantation. In this prospective interventional national cohort study, 44 pediatric liver transplant recipients with measles IgG antibodies

Acute Kidney Injury after Liver Transplantation.

Since the implementation of the MELD score-based allocation system, the number of transplant candidates with impaired renal function has increased. The aims of this review are to present new insights in the definitions and predisposing factors that result in acute kidney injury (AKI), and to propose guidelines for the prevention and treatment of post liver transplantation (LT) AKI. This review is based on both systematic review of relevant literature and expert opinion. Pretransplant AKI is associated with ...

Celiac Axis Extension Grafts in Orthotopic Liver Transplantation.

Reversibility of Acquired Hepatocerebral Degeneration After Liver Transplantation.

Liver Transplantation for Alcoholic Hepatitis - Being Consistent About Where to Set the Bar.

Coronary Artery Disease in Decompensated Patients Undergoing Liver Transplantation Evaluation.

Post-transplant liver graft schistosomiasis in a migrant from Sub-Saharan Africa, Italy 2017.

We report a case of post-transplant liver graft infection with Schistosoma spp in a migrant from Sub-Saharan Africa transplanted for HBV-related cirrhosis and with undiagnosed schistosomiasis pre-transplantation. The occurrence of tropical diseases in non-endemic areas warrants screening protocols for organ donors and recipients with a history of exposure in endemic areas. This article is protected by copyright. All rights reserved.

Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC.

Liver transplantation (LT) is a complex yet curative treatment for a subset of patients with hepatocellular carcinoma (HCC). Due to donor organ shortage, patients with HCC need to be carefully selected for LT. In European countries, selection of patients is based on the Milan criteria, and donor organs are allocated by Eurotransplant. In order to optimize the utilization of available liver grafts, the outcome of HCC patients after LT needs to be closely monitored and evaluated.

Liver Transplantation and Bariatric Surgery: Timing and Outcomes.

Non-alcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the next decade in the United States. Strategies to treat the underlying etiology of NASH, which is almost always obesity, are being pursued. One such strategy is the utilization of bariatric surgery in the peri-transplant period. The use of bariatric surgery prior to LT could prevent the progression of NASH, and abrogate the need for LT. Bariatric surgery at the time of LT or post-operativel...

Strategies that reduce 90-day readmissions and inpatient costs after liver transplantation.

Liver transplantation is hospital-resource intensive and associated with high rates of readmission. We have previously shown a reduction in 30-day readmission rates by implementing a specifically designed protocol to increase access to outpatient care.

Do you really know what you get: the benefits and doubts of Domino Liver Transplantation.

Liver transplantation (LT) has perhaps been the first long-term clinically successful gene-therapy to provide patients with an in-born error of metabolism a near normal life. Some of these metabolic defects with an indication for liver transplantation are associated with an otherwise structurally and functionally complete normal liver. With these scenarios the concept of domino liver transplantation has been established. The liver of the recipient with a liver based metabolic disease can be "recycled" and t...

Liver Transplantation Today: Where we are now and where we are going.

The recent years have been full of remarkable innovation and progress in the field of liver transplant. Importantly, 2017 will always be most significantly remembered, for the loss of the man that paved the way for liver transplantation. On March 4, 2017, Dr. Thomas Starzl passed away at the age of 90, leaving a legacy of unprecedented creativity, bravery, and innovation leading the way for the era of modern transplantation. His impact on patients with end stage organ disease has changed the face of modern ...

Risk Analysis for Invasive Fungal Infection after Living Donor Liver Transplantation: Which Patient Needs Potent Prophylaxis?

Invasive fungal infection (IFI) is associated with high mortality after living donor liver transplant (LDLT). The aim of this study was to identify the risk factors for post-LDLT IFI for early diagnosis and improvement of antifungal treatment outcome.

Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report.

Post transplantation lymphoproliferative disorder (PTLD) is a rare but severe complication. Epstein-Barr virus (EBV) is considered an important pathogen for PTLD and EBV deoxyribonucleic acid (DNA) load is widely monitored to detect PTLD early. Hepatitis B virus (HBV) infection is rarely reported to be related with PTLD. We report a case of EBV negative (EBV), HBV positive (HBV) diffuse large B cell lymphoma in a patient 12 years after liver transplantation.

Auxiliary Partial Orthotopic Liver Transplantation for Selected Non Cirrhotic Metabolic Liver Disease: No Longer Stepping Through the Looking Glass?

Auxiliary Partial Orthotopic Liver Transplantation (APOLT) in selected non-cirrhotic metabolic liver diseases (NCMLD) is a viable alternative to orthotopic liver transplantation as it supplements the function of the native liver with the missing functional protein. APOLT for NCMLD is not universally accepted due to concerns of increased technical complications and long-term graft atrophy.

Viability criteria for functional assessment of donor livers during normothermic machine perfusion.

Persisting donor organ shortage has led to an increased utilization of suboptimal donor livers for transplantation. Transplantation of these extended-criteria donor (ECD) livers, however, is associated with high rates of complications, including early allograft dysfunction (EAD) and primary nonfunction (PNF). As a result, a large number of ECD livers are discarded. This article is protected by copyright. All rights reserved.

Quick Search